Biogen's 2025 Financials Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 08 2026
0mins
Should l Buy BIIB?
Source: NASDAQ.COM
- Strong Financial Performance: Biogen's Q4 2025 report revealed total revenue of nearly $2.28 billion, down 7% year-over-year, yet surpassing analyst expectations of $2.21 billion, demonstrating the company's resilience in challenging market conditions.
- Declining Net Income: Non-GAAP net income fell to $294 million ($1.99 per share), a significant drop from over $502 million a year ago, reflecting increased competitive pressures impacting profitability.
- Product Revenue Decline: Product revenue decreased by 9% to $1.67 billion, with the largest drug category, multiple sclerosis (MS) treatments, experiencing a 14% year-over-year decline to $917 million, highlighting the impact of generics and biosimilars on sales.
- Positive 2026 Outlook: Biogen anticipates mid-single-digit revenue decline for 2026, with adjusted net income projected between $15.25 and $16.25 billion, exceeding the average analyst estimate of $14.92 billion, indicating growth potential in its new product lines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 188.240
Low
143.00
Averages
204.45
High
246.00
Current: 188.240
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
Stoke and Biogen Release Zorevunersen Study Data
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
See More
Zorevunersen Shows Promise for Dravet Syndrome Treatment
- Clinical Trial Results: The Phase 1/2a studies of zorevunersen in Dravet syndrome patients demonstrated significant reductions in seizure frequency among those treated with a 70 mg dose, with effects persisting through three years in the open-label extension, indicating its potential as the first disease-modifying therapy.
- Cognitive and Behavioral Improvements: Results indicate that zorevunersen not only reduces seizures but also significantly improves cognition, behavior, and quality of life across multiple measures, potentially altering the life trajectory for patients and their families by enhancing daily living skills.
- Safety Data: Among 81 patients treated with zorevunersen, over 800 doses were administered, showing overall good tolerability; while 44% of patients in the open-label studies experienced elevated cerebrospinal fluid protein levels, no related clinical manifestations were observed, indicating a favorable safety profile.
- Future Research Directions: Stoke Therapeutics anticipates releasing results from the Phase 3 EMPEROR study in mid-2027, aiming to further validate the efficacy and safety of zorevunersen, thereby providing new treatment options for patients with Dravet syndrome.
See More
Market Dynamics and Investment Opportunities Analysis
- Blue Owl Capital Loan Sales: Blue Owl Capital's loan sales are part of a plan to return capital to investors, and while observers have raised 'canary in the coal mine' warnings regarding mispriced private credit loans, the situation does not appear tragic, potentially offering market opportunities.
- Weak U.S. GDP: The preliminary fourth-quarter U.S. GDP growth came in at just 1.4%, significantly below expectations, with the government shutdown likely dragging on growth, leading to market concerns about future economic recovery challenges.
- Texas Roadhouse Strong Performance: Texas Roadhouse shares rose over 3% in early trading, as the market overlooked a weak fourth quarter due to a strong start in Q1, indicating sustained consumer demand for dining despite ongoing beef inflation challenges.
- Klarna's Disappointing Earnings: Klarna reported a wider-than-expected net loss for the quarter, and its fiscal 2026 outlook fell short across key metrics, prompting JPMorgan and UBS to cut their price targets to $20, reflecting market concerns about its future performance.
See More
Biogen Elects New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company post-2026 Annual Meeting, which is expected to drive ongoing strategic development.
- New Chair's Background: Dr. Freire, who joined the Biogen Board in 2021, brings extensive experience in biomedical innovation and drug development, and is anticipated to leverage her expertise to guide the company through several key project advancements in the next 18 months, including potential filings in lupus and nephrology.
- Former Chair's Contributions: Caroline Dorsa's 16-year tenure on the Board has significantly enhanced innovation and shareholder value, and Dr. Freire's succession is viewed as a natural choice at a critical juncture for the company's transformation and growth, aiming to maintain and strengthen its competitive edge in the biopharmaceutical industry.
- Future Outlook: Under Dr. Freire's leadership, Biogen plans to continue advancing its sustainable growth strategy, particularly in new drug development and market expansion, which is expected to create long-term value for shareholders while addressing public health challenges.
See More
Biogen Elects Dr. Maria C. Freire as New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as the new Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company following the 2026 Annual Meeting, which is expected to drive ongoing strategic development.
- Dorsa's Contributions: Caroline Dorsa has served on Biogen's Board for 16 years, during which she has advanced innovative drug development and enhanced shareholder value, fostering a culture of transparency and trust that lays a solid foundation for future leadership transitions.
- Freire's Background: The new Chair, Dr. Freire, brings extensive experience in biomedical innovation and drug development, having held leadership roles in several key organizations, and her expertise is expected to provide crucial support for Biogen's long-term growth and sustainability.
- Future Outlook: Dr. Freire noted that Biogen is at a critical growth juncture, with multiple clinical trial readouts anticipated in the next 18 months, including potential filings in lupus and nephrology, signaling new opportunities for the company.
See More
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
Stoke and Biogen Release Zorevunersen Study Data
- Study Results Released: Stoke Therapeutics and Biogen announced the publication of data on the investigational drug Zorevunersen, indicating its potential for disease modification in patients with Dravet syndrome, marking a significant advancement in treatment options.
- Clinical Trial Data: Results from two completed Phase 1/2a trials and ongoing open-label extension studies demonstrated substantial and durable reductions in seizures, along with improvements across multiple cognitive and behavioral measures, indicating long-term efficacy.
- Future Research Outlook: Barry Ticho, Chief Medical Officer of Stoke, stated that Zorevunersen could become the first disease-modifying medicine for Dravet syndrome, with anticipation for the Phase 3 EMPEROR study results expected in mid-2027 to further validate its efficacy.
- Market Reaction: Stoke shares closed at $34.42 on Nasdaq, up 1.89%, reflecting positive market expectations regarding the drug's potential.
See More
Zorevunersen Shows Promise for Dravet Syndrome Treatment
- Clinical Trial Results: The Phase 1/2a studies of zorevunersen in Dravet syndrome patients demonstrated significant reductions in seizure frequency among those treated with a 70 mg dose, with effects persisting through three years in the open-label extension, indicating its potential as the first disease-modifying therapy.
- Cognitive and Behavioral Improvements: Results indicate that zorevunersen not only reduces seizures but also significantly improves cognition, behavior, and quality of life across multiple measures, potentially altering the life trajectory for patients and their families by enhancing daily living skills.
- Safety Data: Among 81 patients treated with zorevunersen, over 800 doses were administered, showing overall good tolerability; while 44% of patients in the open-label studies experienced elevated cerebrospinal fluid protein levels, no related clinical manifestations were observed, indicating a favorable safety profile.
- Future Research Directions: Stoke Therapeutics anticipates releasing results from the Phase 3 EMPEROR study in mid-2027, aiming to further validate the efficacy and safety of zorevunersen, thereby providing new treatment options for patients with Dravet syndrome.
See More
Market Dynamics and Investment Opportunities Analysis
- Blue Owl Capital Loan Sales: Blue Owl Capital's loan sales are part of a plan to return capital to investors, and while observers have raised 'canary in the coal mine' warnings regarding mispriced private credit loans, the situation does not appear tragic, potentially offering market opportunities.
- Weak U.S. GDP: The preliminary fourth-quarter U.S. GDP growth came in at just 1.4%, significantly below expectations, with the government shutdown likely dragging on growth, leading to market concerns about future economic recovery challenges.
- Texas Roadhouse Strong Performance: Texas Roadhouse shares rose over 3% in early trading, as the market overlooked a weak fourth quarter due to a strong start in Q1, indicating sustained consumer demand for dining despite ongoing beef inflation challenges.
- Klarna's Disappointing Earnings: Klarna reported a wider-than-expected net loss for the quarter, and its fiscal 2026 outlook fell short across key metrics, prompting JPMorgan and UBS to cut their price targets to $20, reflecting market concerns about its future performance.
See More
Biogen Elects New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company post-2026 Annual Meeting, which is expected to drive ongoing strategic development.
- New Chair's Background: Dr. Freire, who joined the Biogen Board in 2021, brings extensive experience in biomedical innovation and drug development, and is anticipated to leverage her expertise to guide the company through several key project advancements in the next 18 months, including potential filings in lupus and nephrology.
- Former Chair's Contributions: Caroline Dorsa's 16-year tenure on the Board has significantly enhanced innovation and shareholder value, and Dr. Freire's succession is viewed as a natural choice at a critical juncture for the company's transformation and growth, aiming to maintain and strengthen its competitive edge in the biopharmaceutical industry.
- Future Outlook: Under Dr. Freire's leadership, Biogen plans to continue advancing its sustainable growth strategy, particularly in new drug development and market expansion, which is expected to create long-term value for shareholders while addressing public health challenges.
See More
Biogen Elects Dr. Maria C. Freire as New Chair of the Board
- Board Leadership Change: Biogen has elected Dr. Maria C. Freire as the new Chair of the Board, succeeding the retiring Caroline Dorsa, marking a pivotal transition for the company following the 2026 Annual Meeting, which is expected to drive ongoing strategic development.
- Dorsa's Contributions: Caroline Dorsa has served on Biogen's Board for 16 years, during which she has advanced innovative drug development and enhanced shareholder value, fostering a culture of transparency and trust that lays a solid foundation for future leadership transitions.
- Freire's Background: The new Chair, Dr. Freire, brings extensive experience in biomedical innovation and drug development, having held leadership roles in several key organizations, and her expertise is expected to provide crucial support for Biogen's long-term growth and sustainability.
- Future Outlook: Dr. Freire noted that Biogen is at a critical growth juncture, with multiple clinical trial readouts anticipated in the next 18 months, including potential filings in lupus and nephrology, signaling new opportunities for the company.
See More
